Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow VERACYTE, INC.

Get SEC filing alerts via email and in your feed for VERACYTE, INC.

VCYT

VERACYTE, INC.

About VERACYTE, INC.

Veracyte, Inc. is a global diagnostics company specializing in molecular tests for cancer and lung diseases. Its core offerings include genomic classifiers for thyroid, prostate, bladder, and lung cancers, delivered via CLIA labs and international in vitro diagnostic products. The company leverages AI, bioinformatics, and extensive clinical data to improve diagnosis, prognosis, and treatment decisions, aiming to enhance patient outcomes and reduce unnecessary procedures.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from VERACYTE, INC.

1
1
VERACYTE, INC. Veracyte Reports 21% Revenue Growth to $139.1 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
VERACYTE, INC. Veracyte Reports 16% Revenue Growth to $517.1 Million for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
VERACYTE, INC. Veracyte Reports 14% Revenue Growth to $131.9 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
VERACYTE, INC. Veracyte Reports $130.2 Million Revenue in Q2 2025, Faces Net Loss Due to Impairment Charge

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
VERACYTE, INC. Veracyte Reports 18% Revenue Growth to $114.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
VERACYTE, INC. Veracyte Reports $24.1 Million Net Income and 23% Revenue Growth for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
VERACYTE, INC. Veracyte Reports 29% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments